On October 19, 2020 Locust Walk Partners reported Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings (Press release, Locust Walk Partners, OCT 19, 2020, View Source;utm_medium=rss&utm_campaign=q3-2020-biopharma-report [SID1234568642]). Our Q3 2020 Report: Global Trends in Biopharma applies the latest data to analyze current activities in the life science deal landscape.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This quarter shaped to be another positive one for biopharma IPOs and strategic transactions across the globe. And in the US, the rapid need to raise capital without the lengthy IPO process brought back a financing vehicle to take small companies public – SPACs.
A few highlights:
US
Private financings saw one of the strongest Q3s on record, and 2019/2020 biopharma IPOs continue to perform well in the public markets, suggesting investors are bullish long-term on new biopharma opportunities
EU
European biotech financings set a historical record this quarter, demonstrating robust equity markets and increased interest in the region
China
In the Chinese stock market, the SSE Composite Index has fully recovered and stabilized while the top 16 pharma companies listed in mainland China peaked out in early August
Japan
Venture financing deals in 2020 continues its record-setting pace in Japan, as it already exceeds all-time high in the volume and value previously set in 2018
We hope you find this latest data that analyzes current activities in the life sciences deal landscape to be helpful.